Astherna is an academic spin-off company, that aims to develop novel RNA therapeutics to prevent or stop the progression of inherited retinal diseases, with an initial focus on Stargardt disease. Astherna is founded by Rob Collin and Carel Hoyng, together with Radboud University Medical Center. Their enthusiasm, knowledge, network and commitment to Astherna are key ingredients to make this enterprise a success
